Hyperuricemia
Conditions
Interventions
Switch from existing uric acid lowering medication to URECE tablets, starting at 0.5 mg/day for 8 weeks. Blood samples will be taken before, 1 day after, 3 days after, 1 week after, 4 weeks after, and
Sponsors
Takasaki University of Health and Welfare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A person who fully understands and agrees to the purpose of this research and possible adverse events as clearly stated in the Research Cooperation Agreement. Those who have signed the consent form for cooperation. Those who are 30 years of age or older at the time of obtaining consent (excluding students of their own schools). Those who are taking existing uric acid lowering medication daily.
Exclusion criteria
Exclusion criteria: If the subject feels that the research itself is a burden to his/her daily life. Subjects who are judged by the principal investigator or sub-investigator to be ineligible for the study. Those who have contraindications to the administration of the study drug URECE Tablets used in the study. Those who have gout attack. Patients with urinary tract stones, or patients with a history of urinary tract stones. Patients with severe hepatic or renal impairment or cardiac disease. Pregnant women and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect on blood uric acid level | — |
Countries
Japan
Contacts
Public ContactSatsuki Kimura
Takasaki University of Health and Welfare Faculty of Pharmacy
Outcome results
None listed